2021
Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm
Spurny B, Vanicek T, Seiger R, Reed MB, Klöbl M, Ritter V, Unterholzner J, Godbersen GM, Silberbauer LR, Pacher D, Klug S, Konadu ME, Gryglewski G, Trattnig S, Bogner W, Lanzenberger R. Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm. NeuroImage 2021, 232: 117913. PMID: 33657450, PMCID: PMC7610796, DOI: 10.1016/j.neuroimage.2021.117913.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsGamma-aminobutyric acidMajor depressive disorderSerotonin reuptake inhibitorsSSRI treatmentPlacebo administrationReuptake inhibitorsGlutamatergic functionGlutamatergic neurotransmissionDepressive disorderNeuroplastic effectsSerotonergic systemNeurotransmitter systemsHealthy subjectsPsychiatric disordersImpaired cognitive flexibilityBrain regionsNeurotransmitter concentrationsCognitive functionWidespread symptomsMemory formationLast dayDisordersDownstream effectsTreatment
2019
The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2018
Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy
Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Translational Psychiatry 2018, 8: 198. PMID: 30242221, PMCID: PMC6155094, DOI: 10.1038/s41398-018-0227-2.Peer-Reviewed Original ResearchConceptsBright light therapyMAO-A levelsBrain MAO-A levelsSeasonal affective disorderPositron emission tomographyMAO-A VTNon-seasonal depressionHealthy controlsLight therapyAffective disordersTreatment of SADMajor depressive disorderBrain monoamine oxidaseCerebral MAODepressive disorderSerotonergic systemPET scansHC groupMilder symptomsPatientsDistribution volumeEmission tomographyMonoamine oxidaseDisordersSignificant reduction
2017
Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
Spies M, James GM, Berroterán-Infante N, Ibeschitz H, Kranz GS, Unterholzner J, Godbersen M, Gryglewski G, Hienert M, Jungwirth J, Pichler V, Reiter B, Silberbauer L, Winkler D, Mitterhauser M, Stimpfl T, Hacker M, Kasper S, Lanzenberger R. Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. The International Journal Of Neuropsychopharmacology 2017, 21: 145-153. PMID: 29045739, PMCID: PMC5793827, DOI: 10.1093/ijnp/pyx085.Peer-Reviewed Original ResearchConceptsKetamine plasma levelsPositron emission tomographyAntidepressant effectsPlasma levelsSerotonin transporterEmission tomographyAntidepressant dosePositron emission tomography scanReal-life patient cohortEmission tomography scanHigh-dose ketamineSerotonin transporter bindingTest-retest variabilityWhole brain regionsAntidepressant dosesAntidepressant mechanismPatient cohortTomography scanSerotonergic systemTransporter bindingHealthy subjectsAnimal studiesHigh dosesKetamineAdministration
2015
Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding
Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. NeuroImage 2015, 111: 505-512. PMID: 25652393, DOI: 10.1016/j.neuroimage.2015.01.049.Peer-Reviewed Original ResearchConceptsPositron emission tomographySerotonin transporterSerotonin releaseRespective projection areasReuptake of serotoninExtracellular serotonin concentrationBilateral parahippocampal gyrusComplex receptor interactionsProtein expression levelsProjection areaSerotonin 1ASerotonergic transmissionSerotonergic effectsSerotonin concentrationsSerotonergic toneRaphe regionSerotonergic neurotransmissionWhole-brain ANOVAReceptor expressionSerotonergic systemSerotonin systemGenotype statusHealthy subjectsSerotonergic structuresParahippocampal gyrus